Demystifying Cara Therapeutics: Insights From 4 Analyst Reviews
Portfolio Pulse from Benzinga Insights
Cara Therapeutics (NASDAQ:CARA) has been reviewed by 4 analysts in the last three months, showing a shift towards a more bullish stance. The average 12-month price target is now $6.25, down from $8.50, indicating a 26.47% decrease. The company, a biotech focused on novel therapeutics for pain and pruritus, faces challenges with a revenue decline of -7.88% and a net margin of -1076.46%, but has a low debt-to-equity ratio of 0.11.
March 28, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cara Therapeutics has seen a shift in analyst sentiment, with a new average price target suggesting a potential downside. Despite financial challenges, its low debt-to-equity ratio may offer some stability.
The decrease in the average price target reflects a bearish outlook from analysts, likely influenced by the company's recent revenue decline and high net margin losses. However, the company's low debt-to-equity ratio is a positive aspect, potentially mitigating some investor concerns.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100